PHARMING GROUP Stock Euronext Amsterdam
Stocks
NL0000377018
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Euronext Amsterdam
|
||
| - EUR | - |
|
| Market Cap | 891M 808M 747M 674M 1.27B 84.03B 1.31B 8.97B 3.56B 44.89B 3.34B 3.27B 142B | P/E 2026 * |
41x | P/E 2027 * | 33.4x |
|---|---|---|---|---|---|
| Enterprise Value | 836M 758M 701M 633M 1.19B 78.87B 1.23B 8.42B 3.34B 42.13B 3.14B 3.07B 134B | EV / Sales 2026 * |
2.16x | EV / Sales 2027 * | 1.84x |
| Free-Float |
98.98% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PHARMING GROUP
| Manager | Title | Age | Since |
|---|---|---|---|
Kenneth Lynard
CEO | Chief Executive Officer | 58 | 29/09/2026 |
Leverne Marsh
CEO | Chief Executive Officer | - | 29/09/2026 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 54 | 01/06/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Barbara Yanni
BRD | Director/Board Member | 71 | 11/12/2020 |
Mark Pykett
BRD | Director/Board Member | 62 | 11/12/2020 |
| Director/Board Member | 60 | 19/05/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.82% | +3.22% | +42.65% | +147.55% | 1,286B | ||
| -0.22% | +1.36% | +43.27% | +90.50% | 688B | ||
| +0.94% | +1.81% | +27.61% | +115.95% | 521B | ||
| +1.22% | +1.94% | +42.37% | +72.64% | 386B | ||
| -0.44% | -0.71% | +59.06% | +44.82% | 364B | ||
| -0.02% | +1.84% | +28.49% | +63.31% | 302B | ||
| +0.58% | +0.18% | +3.68% | +38.62% | 287B | ||
| +0.82% | +1.19% | +37.77% | +75.00% | 252B | ||
| +1.07% | +0.59% | +37.26% | +128.56% | 208B | ||
| Average | +0.52% | +2.08% | +35.80% | +86.33% | 477B | |
| Weighted average by Cap. | +0.50% | +3.26% | +38.14% | +100.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 387M 351M 325M 293M 552M 36.52B 571M 3.9B 1.55B 19.51B 1.45B 1.42B 61.93B | 422M 382M 354M 319M 601M 39.79B 623M 4.25B 1.68B 21.26B 1.58B 1.55B 67.47B |
| Net income | 26.77M 24.26M 22.44M 20.25M 38.15M 2.52B 39.5M 270M 107M 1.35B 100M 98.33M 4.28B | 28.8M 26.1M 24.14M 21.78M 41.05M 2.72B 42.49M 290M 115M 1.45B 108M 106M 4.6B |
| Net Debt | -54.72M -49.58M -45.86M -41.38M -77.98M -5.16B -80.73M -551M -218M -2.76B -205M -201M -8.75B | -115M -104M -96.5M -87.07M -164M -10.86B -170M -1.16B -460M -5.8B -432M -423M -18.41B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
















